Literature DB >> 8835254

Circulating levels of interleukin 1 beta and of interleukin 1 receptor antagonist in systemic juvenile chronic arthritis.

F De Benedetti1, P Pignatti, M Massa, P Sartirana, A Ravelli, A Martini.   

Abstract

OBJECTIVE: To measure circulating interleukin 1 beta (IL-1 beta) and IL-1 receptor antagonist (IL-1Ra) levels in patients with systemic juvenile chronic arthritis (JCA) and to evaluate their correlation with disease activity.
METHODS: IL-1 beta and IL-1Ra levels were measured by ELISA in 45 patients with JCA (20 systemic, 10 polyarticular and 15 pauciarticular) and in 15 healthy controls.
RESULTS: Plasma IL-1 beta levels were undetectable in the majority of patients with systemic JCA, and detectable levels were not associated with different treatments or with parameters of disease severity. Serum IL-1Ra levels were markedly increased in patients with systemic JCA and significantly correlated with the persistence of systemic features, the extent and severity of joint involvement, and with C-reactive protein concentrations. Serum IL-1Ra levels were also significantly correlated with IL-6 levels.
CONCLUSION: These results argue against a relevant role of IL-1 in systemic JCA. The increase in IL-1Ra levels does not appear to reflect an increase in IL-1 production, but may rather be induced by IL-6.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8835254

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  13 in total

1.  Protective effect of recombinant human IL-1Ra on CCl4-induced acute liver injury in mice.

Authors:  Run-Zhi Zhu; Di Xiang; Chao Xie; Jing-Jing Li; Jian-Jun Hu; Hong-Lin He; Yun-Sheng Yuan; Jin Gao; Wei Han; Yan Yu
Journal:  World J Gastroenterol       Date:  2010-06-14       Impact factor: 5.742

Review 2.  The use of anakinra in juvenile arthritis.

Authors:  Andreas Reiff
Journal:  Curr Rheumatol Rep       Date:  2005-12       Impact factor: 4.592

3.  Interleukin-1 in monocyte activation phenotypes in systemic juvenile idiopathic arthritis: Observations from a clinical trial of rilonacept, an interleukin-1 inhibitor.

Authors:  Yujuan Zhang; Saloni Gupta; Alexandra Ilstad-Minnihan; Sashi Ayyangar; Arielle D Hay; Virginia Pascual; Norman T Ilowite; Claudia Macaubas; Elizabeth D Mellins
Journal:  Clin Immunol       Date:  2018-06-19       Impact factor: 3.969

4.  Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein.

Authors:  C Gabay; M F Smith; D Eidlen; W P Arend
Journal:  J Clin Invest       Date:  1997-06-15       Impact factor: 14.808

5.  Cytokines and juvenile idiopathic arthritis.

Authors:  Patricia Woo
Journal:  Curr Rheumatol Rep       Date:  2002-12       Impact factor: 4.592

Review 6.  Use of biologics in the treatment of childhood rheumatic diseases.

Authors:  T Arkachaisri; T J Lehman
Journal:  Curr Rheumatol Rep       Date:  2000-08       Impact factor: 4.592

7.  Tocilizumab: The evidence for its place in the treatment of juvenile idiopathic arthritis.

Authors:  Troels Herlin
Journal:  Core Evid       Date:  2010-06-15

8.  The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis.

Authors:  D Fishman; G Faulds; R Jeffery; V Mohamed-Ali; J S Yudkin; S Humphries; P Woo
Journal:  J Clin Invest       Date:  1998-10-01       Impact factor: 14.808

9.  Study of pro-inflammatory (TNF-alpha, IL-1alpha, IL-6) and T-cell-derived (IL-2, IL-4) cytokines in plasma and synovial fluid of patients with juvenile chronic arthritis: correlations with clinical and laboratory parameters.

Authors:  N Kutukculer; S Caglayan; F Aydogdu
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

10.  IL1RN Variation Influences Both Disease Susceptibility and Response to Recombinant Human Interleukin-1 Receptor Antagonist Therapy in Systemic Juvenile Idiopathic Arthritis.

Authors:  Victoria L Arthur; Emily Shuldiner; Elaine F Remmers; Anne Hinks; Alexei A Grom; Dirk Foell; Alberto Martini; Marco Gattorno; Seza Özen; Sampath Prahalad; Andrew S Zeft; John F Bohnsack; Norman T Ilowite; Elizabeth D Mellins; Ricardo Russo; Claudio Len; Sheila Oliveira; Rae S M Yeung; Alan M Rosenberg; Lucy R Wedderburn; Jordi Anton; Johannes-Peter Haas; Angela Rösen-Wolff; Kirsten Minden; Ann Marie Szymanski; Wendy Thomson; Daniel L Kastner; Patricia Woo; Michael J Ombrello
Journal:  Arthritis Rheumatol       Date:  2018-06-28       Impact factor: 10.995

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.